Literature DB >> 21707555

Medication prescribed to people with personality disorder: the influence of patient factors and treatment setting.

M J Crawford1, S Kakad, C Rendel, N A Mansour, M Crugel, K W Liu, C Paton, T R E Barnes.   

Abstract

OBJECTIVE: To examine the extent of use and clinical rationale for the prescribing of psychotropic drugs for people with personality disorder (PD) who are in contact with mental health services.
METHOD: Clinical records of 278 patients with a primary diagnosis of PD were examined.
RESULTS: Just over 80% (N = 225) of patients were being prescribed psychotropic medication. One in five was prescribed three or more drugs. People with comorbid mental disorders were more likely to receive psychotropic medication. Half those prescribed antidepressants had no record of depression in their records. While drug treatments were mostly prescribed for depressive and psychotic symptoms, they were also used to try to manage behavioural problems such as self-harm or given in response to patient requests for treatment. People receiving specialist PD services (OR = 0.35, 95% CI = 0.13-0.95) or other specialist services (OR = 0.24, 95% CI = 0.10-0.60) were less likely to be prescribed drug treatments.
CONCLUSION: Drug treatments are widely used for people with PD despite the relatively weak evidence base. Both the type of personality problem and the context in which treatment is delivered appear to have an impact on whether drug treatments are prescribed.
© 2011 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21707555     DOI: 10.1111/j.1600-0447.2011.01728.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  6 in total

1.  The clinical effectiveness and cost effectiveness of clozapine for inpatients with severe borderline personality disorder (CALMED study): a randomised placebo-controlled trial.

Authors:  Mike J Crawford; Verity C Leeson; Rachel Evans; Barbara Barrett; Aisling McQuaid; Jack Cheshire; Rahil Sanatinia; Gary Lamph; Piyal Sen; Katina Anagnostakis; Louise Millard; Inti Qurashi; Fintan Larkin; Nusrat Husain; Paul Moran; Thomas R E Barnes; Carol Paton; Zoe Hoare; Marco Picchioni; Simon Gibbon
Journal:  Ther Adv Psychopharmacol       Date:  2022-04-29

2.  Lamotrigine versus inert placebo in the treatment of borderline personality disorder: study protocol for a randomized controlled trial and economic evaluation.

Authors:  Mike J Crawford; Rahil Sanatinia; Barbara Barrett; Sarah Byford; Gillian Cunningham; Kavi Gakhal; Geof Lawrence-Smith; Verity Leeson; Fenella Lemonsky; Georgia Lykomitrou; Alan Montgomery; Richard Morriss; Carol Paton; Wei Tan; Peter Tyrer; Joseph G Reilly
Journal:  Trials       Date:  2015-07-18       Impact factor: 2.279

3.  Prescribing for personality disorder: qualitative study of interviews with general and forensic consultant psychiatrists.

Authors:  Lawrence Martean; Chris Evans
Journal:  Psychiatr Bull (2014)       Date:  2014-06

4.  Comparing psychotropic medication prescribing in personality disorder between general mental health and psychological services: retrospective cohort study.

Authors:  Giouliana Kadra-Scalzo; Jacqueline Garland; Stephen Miller; Chin-Kuo Chang; Marcella Fok; Richard D Hayes; Paul Moran; Hitesh Shetty; Allan H Young; Robert Stewart
Journal:  BJPsych Open       Date:  2021-03-25

5.  Twenty-Year Trends in the Psychopharmacological Treatment of Outpatients with Borderline Personality Disorder: A Cross-Sectional Naturalistic Study in Spain.

Authors:  Juan C Pascual; Ana Martín-Blanco; Joaquim Soler
Journal:  CNS Drugs       Date:  2021-08-09       Impact factor: 5.749

6.  Prescribing in personality disorder: patients' perspectives on their encounters with GPs and psychiatrists.

Authors:  Dipen Patel; Haroula Konstantinidou
Journal:  Fam Med Community Health       Date:  2020-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.